Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

Overview of attention for article published in Blood, April 2014

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 40,239 followers.

The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line... http://t.co/TVoPVZniRV

Low-dose alemtuzumab plus chemo prolongs PFS in high risk #CLL http://t.co/SBiBKl8dGm

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.